ANI Pharmaceuticals (NASDAQ:ANIP) stock observed trading -29.28% off 52-week high price. On the other end, the stock has been noted 18.04% away from low price over the last 52-weeks. The stock disclosed a move of 2.96% away from 50 day moving average and -11.95% away from 200 day moving average. Moving closer, we can see that shares have been trading 3.15% off 20-day moving average. It has market cap of $723.86M.
On Jan. 24, 2020, ANI Pharmaceuticals (NASDAQ:ANIP) notified the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg. The current annual U.S. market for this product is approximately $101 million, according to IQVIA.
Arthur S. Przybyl, ANI’s President and CEO commented, This is our second generic product launch in 2020 and comes from the recently announced acquisition of 23 commercial and pipeline drugs. This is also the second of two drugs that was developed by Inventia Healthcare Limited as part of a manufacturing and commercialization partnership that includes our recently launched Paliperidone Extended Release tablets. The launch of Tolterodine ER capsules expands our commercial generic portfolio to 48 drugs.
About Tolterodine Extended-Release Capsules
Tolterodine Tartrate Extended-Release Capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
The USA based company ANI Pharmaceuticals moved with change of -0.26% to $61.5 with the total traded volume of 85753 shares in recent session versus to an average volume of 160.20K shares. The stock was observed in the 5 days activity at 0.57%. The one month performance of stock was -3.67%. ANIP’s shares are at -21.36% for the quarter and driving a 15.62% return over the course of the past year and is now at -0.28% since this point in 2018. Right now the stock beta is 1.98. The average volatility for the week and month was at 2.55% and 3.37% respectively. There are 11.77M shares outstanding and 9.33M shares are floated in market.